The new company, named Augustine Therapeutics, is a Vlaams Instituut voor Biotechnologie (VIB) and Katholieke Universiteit (KU) Leuven spin-off. Funded with €4.2m from mainly local investors, Augustine’s first priority is finding new therapeutics for patients suffering from Charcot-Marie-Tooth disease, a hereditary motor and sensory neuropathy of the peripheral nervous system.
Truffle’s BioMedTech fund filled with €250m
Latest NewsParis-based European venture capital company Truffle Capital closed its €250m BioMedTech fund – celebrating its company building approach.
Cellestia: €20m to get to Phase II
Latest NewsBasel-based biopharma company Cellestia Biotech AG has successfully closed a Series B financing round, raising a total of CHF 20 million.
Setting trends with eco-fashion
BackgroundEnzymes have been used widely for years to bleach textiles or shrink wool. However, the clothing sector is one of the world’s most polluting industries. And now fashion labels are turning increasingly to sustainable biofabrication and biotech-inspired methods to help lower the environmental footprint of their products.
Inceptua: Risen through the ranks
AppointmentsLuxembourg-based Inceptua has named Stefan Fraenkel as its new CEO. Fraenkel has been in charge of creating the Inceptua’s business unit Inceptua Pharma since 2017.
Biomarker identifies residual congestion in heart failure patients
Latest NewsData from 1,200 heart failure patients demonstrate that high discharge levels of the biomarker bio-ADM® (bioactive Adrenomedullin) indicate residual congestion in heart failure patients.
Access instead of bureaucracy
OpinionA newly forming industry association warns the European Commission not to block patients’ access to the emerging EU market for medicinal cannabis. At the BIO-Europe in Hamburg, European Biotechnology spoke with one of the initiators, Peter Homberg.
Belgian start-up takes fight on neuropathies
Latest NewsThe new company, named Augustine Therapeutics, is a Vlaams Instituut voor Biotechnologie (VIB) and Katholieke Universiteit (KU) Leuven spin-off. Funded with €4.2m from mainly local investors, Augustine’s first priority is finding new therapeutics for patients suffering from Charcot-Marie-Tooth disease, a hereditary motor and sensory neuropathy of the peripheral nervous system.
Council presses EC to decide on genome editing
BackgroundAfter years of regulatory deadlock concerning political decision making on genome-edited and genetically targeted mutational breeding, the European Council has demanded that the European Commission regulate new plant breeding techniques (NBT), such as oligonucleotid-directed mutagenesis (ODM), gene scissors (CRISPR), and others.
Second clinical failure of Transgene in 2019
Latest NewsFrench Transgene SA said it has terminated its lead programme TG4010 in combination with chemotherapy and checkpoint inhibition.
Its simply mind over matter, guys!
OpinionThe European biotech sector is flourishing – rising stock prices, big partnering deals, and some major M&A. Can someone please tell European fund managers that investing in biotech is simply mind over matter?!